Indane derivatives for antipsychotic compositions

Details Indane derivatives for antipsychotic compositions Indane derivatives for antipsychotic compositions

2000-09-05

2002-08-06

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S162000, C546S206000, C546S281100, C546S314000, C546S315000, C546S316000, C548S567000, C548S568000, C549S057000, C549S072000, C564S080000, C564S092000, C564S093000, C564S162000, C514S319000, C514S343000, C514S353000, C514S355000, C514S428000, C514S438000, C514S443000, C514S444000, C514S448000, C514S522000, C514S523000, C514S524000, C514S604000

Reexamination Certificate

active

06429317

ABSTRACT:

The present invention relates to novel indane-like compounds and to formulations containing such indane-like compounds as an active ingredient for pharmaceutical or veterinary use.
Currently there are many drugs available for the treatment of disorders of the central nervous system. Amongst these drugs is a category known as antipsychotics for treating serious mental conditions such as psychosis, including but not limited to schizophrenia and schizophreniform illnesses. The skilled artisan will recognize that these psychotic conditions are characterized by hallucinations, delusions, or grossly disorganized behavior which indicate that the patient suffers from gross impairment in reality testing. Drugs having said antipsychotic activity can be useful for treating a variety of important psychotic disorders. The drugs commercially available for such conditions are often associated with undesirable side effects. There is a need for additional therapeutic choices to control or eliminate the symptoms in the safest and most effective way. Furthermore, patients often do not respond or only partially respond to present drug treatment, and estimates of such partial- or non-responders has varied between 40% and 80% of those treated.
Ever since antipsychotics were introduced it has been observed that patients are liable to suffer from drug-induced extrapyramidal symptoms which include drug-induced Parkinsonism, acute dystonic reactions, akathisia, tardive dyskinesia and tardive dystonia. The Simpson Angus Scale, Barnes Akathisia Rating Scale and Abnormal Involuntary Movement Scale (AIMS) are well known scales for assessing extrapyramidal symptoms. The great majority of drugs available for treatment of schizophrenia are prone to produce these extrapyramidal side effects when used at dosages that yield a beneficial effect on the symptoms of the disease. The severity of adverse events and/or lack of efficacy in a considerable number of patients frequently results in poor compliance or termination of treatment.
Many of the drugs are associated with a sedative effect and may also have an undesirable influence on the affective symptoms of the disease, causing depression. In some instances long term use of the drug leads to irreversible conditions, such as the tardive dyskinesia and tardive dystonia referred to supra.
A widely-used antipsychotic, haloperidol, is one such drug, which has been reported as causing a high incidence of extrapyramidal symptoms and may also cause tardive dyskinesia. More recently, clozapine, one of a large group of heterocyclic antipsychotics, has been introduced with the claim that it is free from extrapyramidal effects. However, the compound was found to cause agranulocytosis in some patients, a condition resulting in a lowered white blood cell count which can be life-threatening, and it may now only be employed under very strict medical observation and supervision.
Therefore, new compounds having antipsychotic activity are highly desired.
The present invention provides a compound of the Formula I:
R
1
is selected from the group consisting of hydrogen, —OR
4
, —SRS, C
1
-C
3
alkyl, C
2
-C
3
alkenyl, halo, —CN, S(O)
m2
, —COR
4b′
, and —OC(O)—R
15
;
m2 is from 0 to 2;
R
2
is selected from the group consisting of C
1
-C
10
alkyl, substituted C
1
-C
10
alkyl, C
2
-C
10
alkenyl, substituted C
2
-C
10
alkenyl, C
3
-C
8
cycloalkyl, substituted C
3
-C
8
cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
R
4
is hydrogen, C
1
-C
3
alkyl;
R
5
is hydrogen, C
1
-C
3
alkyl;
R
10
is selected from the group consisting of hydrogen, carbonyl, halo, and C
1
-C
3
alkyl;
R
11
is selected from the group consisting of hydrogen and C
1
-C
3
alkyl;
R
12
is independently selected from the group consisting of hydrogen, C
1
-C
10
alkyl, and aryl;
R
13
is independently selected from the group consisting of hydrogen, C
1
-C
10
alkyl, and aryl; or
R
12
and R
13
together with the nitrogen to which they are attached form a group of the formula II:
 or
 or II′ wherein the II′ group is a group of Formula II which is unsaturated; or
R
11
and R
12
together with the nitrogen and carbon to which they are bound can join to form a three to six membered ring;
R
14
is selected from the group consisting of H, halo, C
1
-C
3
alkyl, S(O)
m3
and —OR
16
;
R
15
is C
1
-C
3
alkyl or aryl;
R
16
is C
1
-C
3
alkyl;
R
17
is independently selected from the group consisting of hydrogen, —OR
4′
, —SR
5′
, C
1
-C
3
alkyl, C
2
-C
3
alkenyl, halo, —CN, S(O)
m2′
, —COR
4b
, and —OC(O)—R
15′
;
R
4b
and R
4b′
are each independently selected from hydrogen and C
1
-C
3
alkyl;
R
15′
is C
1
-C
3
alkyl or aryl;
m2′ is 0 to 2;
R
4′
is hydrogen, C
1
-C
3
alkyl;
R
5′
is hydrogen, C
1
-C
3
alkyl;
m2 is 0 to 2;
X is selected from the group consisting of CH
2
, O, S, NH, carbonyl, and a bond;
n′ is 0 to 2;
m′ is 0 to 2;
m3 is 0 to 2;
n is 0 to 3; or
a pharmaceutically acceptable salt or solvate thereof.
Further, the invention provides a method for treating psychosis comprising administering a compound of Formula I to a mammal in need of such treatment.
Additionally, the present invention provides a method for interacting with a muscarinic receptor comprising administering a compound of Formula I.
Finally, the invention provides a formulation containing a compound of Formula I as an active ingredient.
Further this invention provides compounds of the Formula III
R
1
is selected from the group consisting of hydrogen, —OR
4
, —SR
5
, C
1
-C
3
alkyl, C
2
-C
3
alkenyl, halo, —CN, S(O)
m2
, —COR
4b′
, and —OC(O)—R
15
;
m2 is from 0 to 2;
R
2
is selected from the group consisting of C
1
-C
10
alkyl, substituted C
1
-C
10
alkyl, C
2
-C
10
alkenyl, substituted C
2
-C
10
alkenyl, C
3
-C
8
cycloalkyl, substituted C
3
-C
8
cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
R
4
is hydrogen, C
1
-C
3
alkyl;
R
5
is hydrogen, C
1
-C
3
alkyl;
R
10
is selected from the group consisting of hydrogen, carbonyl, halo, and C
1
-C
3
alkyl;
R
11
is selected from the group consisting of hydrogen and C
1
-C
3
alkyl;
R
12
is independently selected from the group consisting of hydrogen, C
1
-C
10
alkyl, and aryl;
R
13
is independently selected from the group consisting of hydrogen, C
1
-C
10
alkyl, and aryl; or
R
12
and R
13
together with the nitrogen to which they are attached form a group of the formula II:
 or II′ wherein the II′ group is a group of Formula II which is unsaturated; or
R
11
and R
12
together with the nitrogen and carbon to which they are bound can join to form a three to six membered ring;
R
14
is selected from the group consisting of H, halo, C
1
-C
3
alkyl, S(O)
m3
and —OR
16
;
R
15
is C
1
-C
3
alkyl or aryl;
R
16
is C
1
-C
3
alkyl;
R
17
is independently selected from the group consisting of hydrogen, —OR
4′
, —SR
5′
, C
1
-C
3
alkyl, C
2
-C
3
alkenyl, halo, —CN, S(O)
m2′
, —COR
4b
, and —OC(O)—R
15′
;
R
4b
and R
4b′
are each independently selected from hydrogen and C
1
-C
3
alkyl;
R
15′
is C
1
-C
3
alkyl or aryl;
m2′ is 0 to 2;
R
4′
is hydrogen, C
1
-C
3
alkyl;
R
5
, is hydrogen, C
1
-C
3
alkyl;
m2 is 0 to 2;
X is selected from the group consisting of CH
2
, O, S, NH, carbonyl, and a bond;
n′ is 0 to 2;
m′ is 0 to 2;
m3 is 0 to 2;
n is 0 to 3; or
a pharmaceutically acceptable salt or solvate thereof.
Additionally, this invention provides a formulation comprising a compound of Formula III and one or more pharmaceutically acceptable excipients or carriers therefor.
Also included is a method for treating a condition associated with the modulation of a muscarinic receptor comprising administering an effective amount of a compound of Formula III to a mammal in need of such treatment.
Additionally, provided is a compound of Formula IV
R
21
and R
22
are sel

Affiliated with

Also associated with

Rating

Indane derivatives for antipsychotic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indane derivatives for antipsychotic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indane derivatives for antipsychotic compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2907419